Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

BRCA2 mutation + HER-2 negative

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

HER-2 amplification (129)

BRCA2 deletion (10)

BRCA2 exon 11 deletion (3)

BRCA2 amplification (2)

EGFR amplification + ERBB2 amplification (1)

EGFR exon 19 deletion + HER-2 amplification (1)

HER-2 amplification + MET amplification (1)

HER-2 amplification + PTEN deletion (1)

HER-2 exon 19 deletion (1)

MYC amplification + HER-2 amplification (1)

BRCA2 deletion + RB1 deletion (1)

HER-2 amplification + CDK12 amplification (0)

YES1 amplification + HER-2 amplification (0)

HER-2 amplification (129)

BRCA2 deletion (10)

BRCA2 exon 11 deletion (3)

BRCA2 amplification (2)

EGFR amplification + ERBB2 amplification (1)

EGFR exon 19 deletion + HER-2 amplification (1)

HER-2 amplification + MET amplification (1)

HER-2 amplification + PTEN deletion (1)

HER-2 exon 19 deletion (1)

MYC amplification + HER-2 amplification (1)

BRCA2 deletion + RB1 deletion (1)

HER-2 amplification + CDK12 amplification (0)

YES1 amplification + HER-2 amplification (0)

›

BRCA2 mutation + HER-2 negative	HER2 Negative Breast Cancer	BRCA2 mutation + HER-2 negative	HER2 Negative Breast Cancer	olaparib Sensitive: B - Late Trials olaparib Sensitive : B	olaparib Sensitive: B - Late Trials olaparib Sensitive : B
BRCA2 mutation + HER-2 negative	Breast Cancer	BRCA2 mutation + HER-2 negative	Breast Cancer	niraparib Sensitive: C3 – Early Trials niraparib Sensitive : C3	niraparib Sensitive: C3 – Early Trials niraparib Sensitive : C3